DK1838341T3 - Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid - Google Patents

Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid

Info

Publication number
DK1838341T3
DK1838341T3 DK06701328.4T DK06701328T DK1838341T3 DK 1838341 T3 DK1838341 T3 DK 1838341T3 DK 06701328 T DK06701328 T DK 06701328T DK 1838341 T3 DK1838341 T3 DK 1838341T3
Authority
DK
Denmark
Prior art keywords
fibronectin binding
vaccine composition
binding protein
binding peptide
peptide
Prior art date
Application number
DK06701328.4T
Other languages
English (en)
Inventor
Bror Morein
Karin Loevgren-Bengtsson
Birgitta Fromgren
Jill Ekstroem
Carlos Baschunan
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of DK1838341T3 publication Critical patent/DK1838341T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK06701328.4T 2005-01-20 2006-01-20 Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid DK1838341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59350405P 2005-01-20 2005-01-20
PCT/SE2006/000082 WO2006078213A1 (en) 2005-01-20 2006-01-20 Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide

Publications (1)

Publication Number Publication Date
DK1838341T3 true DK1838341T3 (da) 2013-11-04

Family

ID=36692518

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06701328.4T DK1838341T3 (da) 2005-01-20 2006-01-20 Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid

Country Status (9)

Country Link
US (2) US8007806B2 (da)
EP (1) EP1838341B1 (da)
CN (1) CN101107009B (da)
BR (1) BRPI0606481A2 (da)
CA (1) CA2592627C (da)
DK (1) DK1838341T3 (da)
ES (1) ES2433467T3 (da)
PL (1) PL1838341T3 (da)
WO (1) WO2006078213A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043690A1 (en) * 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN102993278B (zh) * 2012-09-29 2014-02-19 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌(MRSA)疫苗重组蛋白抗原FnbA1的纯化方法
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
CN106680483A (zh) * 2015-11-06 2017-05-17 中创云牧(内蒙古)科技咨询有限公司 金黄色葡萄球菌黏附素蛋白抗体的抗黏附能力的检测方法
CA3015639A1 (en) * 2016-03-09 2017-09-14 Technion Research And Development Foundation Ltd. Liposomal formulations and methods of using same in agriculture
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
CA3197371A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
SE2200142A1 (en) * 2022-12-13 2024-06-14 Savacc Ab Chrisvacc

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
EP0444174A4 (en) 1989-09-08 1992-09-16 Wisconsin Alumni Research Foundation Test for the detection of staphylococcal fibronectin-receptor antibodies
NL9000207A (da) * 1990-01-29 1991-08-16 Duphar Int Res
US5270168A (en) * 1990-02-21 1993-12-14 Board Of Regents, The University Of Texas System Method for diagnosing non-healing ulcers
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US5618916A (en) 1993-01-06 1997-04-08 The Jewish Hospital Of St. Louis Purified protein which functions as a mycobacterial receptor for fibronectin
AU1991095A (en) 1994-03-09 1995-09-25 Pacific Biotech International, Inc. Activating virus
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
US5753235A (en) 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6288214B1 (en) * 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
EP0835930B1 (en) 1996-10-09 2001-01-31 Akzo Nobel N.V. European vaccine strains of the porcine reproductive and respiratory syndrome virus (PRRSV)
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003269839B2 (en) 2002-10-02 2006-07-27 Nordic Vaccine A/S Composition for vaccination
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
CN101107009B (zh) 2014-08-06
ES2433467T3 (es) 2013-12-11
WO2006078213A1 (en) 2006-07-27
US20110303563A1 (en) 2011-12-15
US20090208562A1 (en) 2009-08-20
EP1838341B1 (en) 2013-08-14
CA2592627C (en) 2014-02-25
CN101107009A (zh) 2008-01-16
CA2592627A1 (en) 2006-07-27
US8007806B2 (en) 2011-08-30
PL1838341T3 (pl) 2014-04-30
US8187585B2 (en) 2012-05-29
EP1838341A1 (en) 2007-10-03
BRPI0606481A2 (pt) 2009-06-30

Similar Documents

Publication Publication Date Title
DK1838341T3 (da) Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
HUS1900035I1 (hu) Kalcitonin gén-rokon peptid ellen irányuló antagonista ellenanyag
EP2093287A4 (en) PEPTIDE BINDER IGG
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
EP2118122A4 (en) NOVEL ANTIMICROBIAL PEPTIDES
DE602005015131D1 (de) Interleukin-15-antagonistisches peptid
EP1961761A4 (en) Novel peptide compound
IL241890A0 (en) Compositions comprising a viral vector containing a recombinant neurotrophic protein
ATE451392T1 (de) Gegen amyloid-beta peptid gerichtete antikörper
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
ATE482281T1 (de) Plastiden transit peptide
PT2339014E (pt) Métodos e composições compreendendo aminoácidos não-naturais
EG26619A (en) PEG-quadrangle arbor polymer for binding to proteins and peptides
ZA200705943B (en) Survivin peptide vaccine
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
DK2001518T3 (da) Cykliske natriuretiske peptidfremstillinger
EP2078082A4 (en) RECOMBINANT HUMAN INTERFERONIAL PROTEINS
EP1735335A4 (en) Cell-killing peptide
ATE547425T1 (de) Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
DE602005012757D1 (de) Antibakterielles Peptid
EP1968623A4 (en) Bacteriocin BROKER PEPTIDE
FI20050753L (fi) Uudet peptidit
EP1939286A4 (en) NEW PEPTIDE
FI20075483A0 (fi) Uusi peptidi
DK2081952T3 (da) Peptider